NRG1 and non-small cell lung carcinoma: Zenocutuzumab is an antibody indicated to treat adult patients with advanced unresectable or metastatic non-small cell lung cancer (NSCLC) harboring a neuregulin 1 (NRG1) gene fusion with disease progression on or after prior systemic therapy [67].